Sokolowska E, Kalaska B, Miklosz J, Mogielnicki A (August 2016). "The toxicology of heparin reversal with protamine: past, present and future". Expert Opinion on Drug Metabolism & Toxicology. 12 (8): 897–909. doi:10.1080/17425255.2016.1194395. PMID27223896. S2CID22038832.
Thachil J (March 2022). "Protamine-The Journey from DNA to Heparin Neutralization to Gene therapy". Seminars in Thrombosis and Hemostasis. 48 (2): 240–243. doi:10.1055/s-0041-1736574. PMID34729729.
World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
Sokolowska E, Kalaska B, Miklosz J, Mogielnicki A (August 2016). "The toxicology of heparin reversal with protamine: past, present and future". Expert Opinion on Drug Metabolism & Toxicology. 12 (8): 897–909. doi:10.1080/17425255.2016.1194395. PMID27223896. S2CID22038832.
Thachil J (March 2022). "Protamine-The Journey from DNA to Heparin Neutralization to Gene therapy". Seminars in Thrombosis and Hemostasis. 48 (2): 240–243. doi:10.1055/s-0041-1736574. PMID34729729.
Sokolowska E, Kalaska B, Miklosz J, Mogielnicki A (August 2016). "The toxicology of heparin reversal with protamine: past, present and future". Expert Opinion on Drug Metabolism & Toxicology. 12 (8): 897–909. doi:10.1080/17425255.2016.1194395. PMID27223896. S2CID22038832.